Adagrasib in KRYSTAL-12 has Not Broken the KRAS G12C Enigma Code of the Unspoken 6-Month PFS Barrier in NSCLC

Mutations in KRAS G12C are among the more common oncogenic driver mutations in non-small cell lung cancer (NSCLC). In December 2022, the US Food and Drug Administration (FDA) granted accelerated approval to adagrasib, a small molecule covalent inhibitor of KRAS G12C, for the treatment of patients wi...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Local and regional anesthesia 2024-01, Vol.15, p.169-176
Hauptverfasser:	Lee, Alexandria T M, Nagasaka, Misako
Format:	Artikel
Sprache:	eng
Schlagworte:	Chemotherapy FDA approval Growth factors Immunotherapy Lung cancer Metastasis Mutation Patients Quality of life
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!